Understanding TROP2-Directed ADC Therapy
Trophoblast Cell Surface Antigen 2 (TROP2) is a cell-surface protein that is highly expressed in multiple solid tumors, including NSCLC and TNBC. Its broad expression across a range of epithelial cancers has made TROP2 an important target for the development of antibody-drug conjugates (ADCs).
ADCs are designed to combine the specificity of monoclonal antibodies with the cell-killing activity of potent cytotoxic agents. By selectively targeting tumor-associated proteins, ADCs may help deliver treatment directly to cancer cells while limiting exposure to normal tissues.
The TROP2-directed ADC component of LFR-1102 consists of three key elements:
- A TROP2-targeting monoclonal antibody
- A linker that connects the antibody to the payload
- A potent cytotoxic payload designed to kill cancer cells
Upon binding to TROP2-expressing tumor cells, the ADC is internalized and releases its payload within the cancer cell, leading to targeted tumor cell death.
How TROP2 ADC Therapy Works
Antibody-drug conjugates are designed to deliver targeted therapy directly to cancer cells through a multi-step process.
01
Target Recognition
The ADC selectively binds to TROP2 proteins expressed on the surface of tumor cells.
02
Internalization
Following binding, the ADC-TROP2 complex is internalized into the cancer cell.
03
Payload Release
Once inside the cell, the cytotoxic payload is released, resulting in targeted tumor cell death.
Combining Two Complementary Approaches
LFR-1102 combines two established therapeutic strategies that attack cancer through complementary mechanisms.
The TROP2-directed ADC component is designed to selectively deliver a cytotoxic payload to tumor cells, while the anti-PD-1 component is designed to help restore anti-tumor immune activity by blocking inhibitory checkpoint signaling.
Together, these approaches may provide a more comprehensive attack on cancer by combining direct tumor cell killing with activation of the immune response.
Targeted Tumor Cell Killing
The ADC component selectively targets TROP2-expressing tumor cells and delivers a cytotoxic payload designed to induce cancer cell death.
Immune Checkpoint Blockade
The anti-PD-1 component is designed to restore T-cell activity and support the immune system’s ability to recognize and attack cancer cells.
Complementary Mechanisms
By combining targeted cytotoxic therapy with immune activation, LFR-1102 is designed to address cancer through multiple biological pathways.
Why NSCLC?
Non-small cell lung cancer is the most common form of lung cancer and remains a leading cause of cancer-related mortality worldwide. Despite significant advances in treatment, many patients with advanced disease continue to experience disease progression and limited long-term outcomes.
TROP2 expression has been observed in NSCLC, and both ADC therapy and immune checkpoint inhibition have emerged as important therapeutic approaches. By combining these two modalities, LFR-1102 is being developed to explore the potential benefits of dual-mechanism treatment in NSCLC.
Why TNBC?
Triple-negative breast cancer is an aggressive subtype of breast cancer characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression. Patients with advanced TNBC often face limited treatment options and a high risk of disease progression.
TROP2 expression has been observed in TNBC, making it an attractive target for ADC therapy. In addition, immunotherapy has become an important treatment modality in selected patients. LFR-1102 is being developed to combine these complementary approaches in TNBC.
Why LFR-1102?
Combining Targeted Therapy and Immunotherapy
LFR-1102 brings together two established therapeutic modalities—targeted ADC therapy and immune checkpoint inhibition—to address cancer through complementary mechanisms.
Established Biological Targets
The program is built upon two clinically validated targets, TROP2 and PD-1, both of which have become important components of modern oncology treatment strategies.
Focused Development Strategy
Liferna is advancing LFR-1102 in NSCLC and TNBC, two cancers where meaningful unmet medical need remains and where both ADC therapy and immunotherapy have demonstrated clinical relevance.
Expanding the Oncology Franchise
LFR-1102 represents the first combination strategy built upon Liferna’s anti-PD-1 platform and serves as an important component of the company’s expanding oncology portfolio.
Clinical Studies
LFR-1102 is supported by publicly reported clinical experience with TROP2-directed ADC therapy and PD-1 checkpoint inhibition. For additional information regarding clinical studies, development activities, and published data, please visit our Clinical Studies section.
Expanding the Oncology Franchise
LFR-1102 builds upon the foundation established by LFR-1101 and represents an important step in the evolution of Liferna’s oncology portfolio.
Related Programs
